The $10 Billion Opportunity: Sustaining Success with Oncology Biosimilars

Planned in cooperation with the ASHP Section of Specialty Pharmacy Practitioners

ACPE Activity Number: 0204-0000-19-017-H04-P
Release Date: June 25, 2019
Expiration Date: June 25, 2022
Activity Type: Knowledge-based  
CE Credits: 1.0 hour, no partial credit
Activity Fee: Members – Free / Non-Member – Not Available  

Accreditation for Pharmacists

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity is a recording from a live webinar and those that claim credit for the live webinar should not claim credit for this activity.

Target Audience

This continuing pharmacy education activity is designed for pharmacists working with oncologic biosimilar products.

Activity Overview

The next meaningful wave of biosimilar launches is rapidly approaching and successful implementation is by no means assured. While the U.S. market has moved beyond the infancy stage, complete maturation still seems far off. The current state of adoption and market competition can best be described as “modest” with numerous legal and financial hurdles limiting market uptake. The consequence of these barriers could be felt even further given the pending launch of biosimilar competition for three of the molecules that have defined the essence of oncology best practice, rituximab, bevacizumab, and trastuzumab. These three agents currently account for over $10 billion in U.S. spend annually. In addition to the operational hurdles described above, the potential for clinically motivated reluctance towards the use of biosimilars could be even greater than what has been witnessed in the supportive care and disease modifying antirheumatic drug space. As such, pharmacists must be prepared to educate oncologists and hematologists to address these concerns and move physicians to a complete state of competence with the biosimilar paradigm. This presentation will describe the pipeline for competing products, the evolving dynamics that are affect use, and the specific considerations that will apply to the oncology biosimilar products.   

Learning Objectives

  • Describe the current trends in the ongoing maturation of the U.S. biosimilars market and the impact of pending clinical, regulatory, and legal actions on continued development.
  • Discuss the anticipated role of biosimilars for the oncology monoclonal antibodies and the unique considerations governing their use in clinical practice.
  • Describe a methodology to engage physicians in supporting the use of biosimilars in the oncology setting.

Schedule of Educational Activities

  • Current trends in the ongoing maturation of the U.S. biosimilars market
  • Impact of pending clinical, regulatory and legal actions on continued development
  • Biosimilars for oncology monoclonal antibodies
  • Methodology to engage physicians in supporting the use of biosimilars in the oncology setting

Faculty Information

  • Steven Lucio, Pharm.D., BCPS, Vice President, Pharmacy Solutions, Vizient, Irving, TX
  • Nathan Leedahl, Pharm.D., BCPS, Lead Pharmacist, Enterprise Pharmacy, Specialty - Drug Access, Sanford Pharmacy Broadway, Fargo, ND

Faculty Disclosures

In accordance with the ACPE's and ACCME's Standards for Commercial Support, anyone in a position to control the content of an educational activity is required to disclose to the accredited provider their relevant financial relationships. In accordance with these Standards, all potential conflicts of interest have been resolved. An individual has a relevant financial relationship if he or she (or spouse/domestic partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the activity content over which the individual has control.

As defined by ACCME, a commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The Standards for Commercial Support do not consider providers of clinical service directly to patients to be commercial interests. The existence or non-existence of relevant financial relationships will be disclosed to the activity audience. All identified conflicts of interest must be resolved prior to the activity.

  • All planners, presenters, reviewers, and ASHP staff report no financial relationships relevant to this activity.

Methods and CE Requirements

This activity consists of a recordings of faculty slides presentations, active learning activities, discussion, and handouts. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP eLearning Portal. Follow the prompts online to complete the evaluation, claim credit and view the statement of credit immediately after completing the activity.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Claim your CE at Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF.  Users should have a basic comfort level using a computer and navigating web sites.

 View the minimum technical and system requirements for learning activities.